{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-065314","form_type":"8-K","ticker":"XOMA","cik":"0000791908","company_name":"XOMA Royalty Corp","filed_at":"2023-03-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:48.097868+00:00","generated_at":"2026-06-18T07:58:30.834370+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"XOMA reports FY 2022 net loss of $17.1M; Vabysmo commercial payments begin","bullets":["FY 2022 revenue $6.0M vs $38.2M in 2021; net loss $17.1M vs net income $15.8M.","Cash $57.8M at Dec 31, 2022; no debt.","Received second Vabysmo commercial payment from Roche in Feb 2023; 0.5% interest in sales.","Ebopiprant deal with Organon offers up to $378M milestones plus mid-single/low-teen royalties.","Executive Chairman Owen Hughes and CIO Brad Sitko added to lead royalty acquisition strategy."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-065314","json":"https://secwatch.observer/filing/0001193125-23-065314.json","markdown":"https://secwatch.observer/filing/0001193125-23-065314.md","text":"https://secwatch.observer/filing/0001193125-23-065314.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/791908/000119312523065314/0001193125-23-065314-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/791908/000119312523065314/d479992d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T07:58:30.834370+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9f3b1b756a9f333bc191cce5bdf48615ec174d2a","claim":"XOMA Royalty Corp reported the quarter and year ended December 31, 2022 results: revenue $1.5 million and $6.0 million, net income Net loss for the fourth quarter and year ended December 31, 2022, was $6.0 million and $17.1 million.","evidence_excerpt":"said Brad Sitko, Chief Investment Officer of XOMA. Fourth Quarter and Full Year 2022 Financial Results Revenues for the fourth quarter and year ended December 31, 2022, were $1.5 million and $6.0 million, respectively. For the full year of 2022, XOMA’s reported revenues were related to milestone payments of $2.0 million from Rezolute, $0.8 million from Takeda,","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/791908/000119312523065314/0001193125-23-065314-index.htm","confidence":0.997,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter and year ended December 31, 2022"},{"label":"Revenue","value":"$1.5 million and $6.0 million"},{"label":"Net income","value":"Net loss for the fourth quarter and year ended December 31, 2022, was $6.0 million and $17.1 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}